ABSTRACT
Medicine developers have an opportunity to gain feedback from regulators and HTA bodies, early in the development process of a medicine. The authorities concerned with these schemes use various terms, such as early dialogue or scientific advice; however these are often specific to an organization and there is no consensus on terminology. In this chapter, we use the general term early HTA advice or the organizationspecific terms when relevant.
